Letrozole, alias femara, is a white or off-white powder of chemicals. It
is a new generation of aromatase inhibitor, which is a synthetic
benzyltriazole derivative. Letrozole can reduce the estrogen level by
inhibiting aromatase, thereby eliminating the stimulating effect of
estrogen on tumor growth. Endocrine therapy for breast cancer.
Femara powder
In vitro and in vivo studies have shown that letrozole can effectively
inhibit the conversion of androgen to estrogen, while estrogen in
postmenopausal women is mainly derived from the aromatization of
androgen precursors in peripheral tissues, so it is especially suitable
for postmenopausal breast cancer. patient. Letrozole is 150-250 times
more potent than the first-generation aromatase inhibitor,
aminoglutethimide. Because of its high selectivity, it does not affect
glucocorticoids, mineralocorticoids and thyroid function. High doses
have no inhibitory effect on the secretion of adrenocortical steroids
and therefore have a higher therapeutic index. Various preclinical
studies have shown that letrozole has no potential toxicity to various
systems and target organs, and has the characteristics of good tolerance
and strong pharmacological action. Letrozole has a stronger antitumor
effect than other aromatase inhibitors and antiestrogens
There is no clinical correlation between gender, age, and liver and
kidney function and letrozole, so elderly patients and patients with
impaired liver and kidney function do not have to adjust the dose.
According to years of clinical experience, it also has
ovulation-promoting effect.
The Wall